TARA
Protara Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.55
−4.05%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.68
From 52W high−53.04%
Volume3.95M
Market cap$209.79M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$3.68
From 52W high
−53.04%
Volume
3.95M
Market cap
$209.79M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.8x
P/E (TTM)
—
RSI (14)
38.8
MomentumView details →
1D Return
−4.05%
YTD Return
−31.24%
SummaryUpdated Jun 1, 2026
Protara Therapeutics, Inc. (NASDAQ:TARA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. Originally incorporated as ArTara Therapeutics, Inc., the company changed its name to Protara Therapeutics in May 2020. The company focuses on identifying and advancing transformative therapies for the treatment of cancer and rare diseases, with a particular emphasis on developing innovative cell therapies and substrate replacement treatments for underserved patient populations.
Similar companies
Latest newsMore news →
Protara Therapeutics reported a net loss of $21.7 million for Q2 2026, with research and development expenses of $17.0 million and general and administrative expenses of $6.4 million.41d agoLeonardo Viana Nicacio, M.D. resigned as Chief Medical Officer of Protara Therapeutics, Inc., effective June 26, 2026.84d ago